Gilead Sciences Inc. (NASDAQ:GILD) has invested in HOOK's antiviral programs, particularly HB-400 and HB-500. They also supported a merger between HOOK and Poolberg Pharma to strengthen their focus on immunotherapies.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing